

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

Caov-3

RRID:CVCL_0201

Type: Cell Line

Proper Citation

RRID:CVCL_0201

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0201

Proper Citation: RRID:CVCL_0201

Description: Cell line Caov-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:3335022](#), [PMID:3518877](#), [PMID:4016745](#), [PMID:9698466](#), [PMID:10318951](#), [PMID:12080474](#), [PMID:18560578](#), [PMID:19926575](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:22328975](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:28196595](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:33519462](#), [PMID:35681748](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Caov-3

Synonyms: CaOv-3, CaOV-3, CAOv-3, CAOv3, CaOV3, CaOv3, Caov3, CA-OV-3, CaOV3 (S)

Cross References: BTO:BTO_0000814, CLO:CLO_0002195, EFO:EFO_0002148, MCCL:MCC:0000119, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ATCC:HTB-75, BioGRID_ORCS_Cell_line:338, BioSample:SAMN03472624, BioSample:SAMN05292465, BioSample:SAMN10988200, cancercellines:CVCL_0201, CancerTools:161926, CCRID:1101HUM-PUMC000339, CCRID:3101HUMSCSP570, CCRID:4201HUM-CCTCC00118, CCTCC:GDC0118, Cell_Model_Passport:SIDM00919, ChEMBL-Cells:ChEMBL3307927, ChEMBL-Targets:ChEMBL614379, CLS:300319, Cosmic:687927, Cosmic:688092, Cosmic:809114, Cosmic:844349, Cosmic:906579, Cosmic:906825, Cosmic:924149, Cosmic:949225, Cosmic:1102821, Cosmic:1139227, Cosmic:1305310, Cosmic:1312190, Cosmic:1707569, Cosmic:1709259, Cosmic:2186585, Cosmic:2301585, Cosmic-CLP:906825, DepMap:ACH-000713, EGA:EGAS00001000610, GDSC:906825, GEO:GSM184398, GEO:GSM184399, GEO:GSM274705, GEO:GSM313711, GEO:GSM459740, GEO:GSM659371, GEO:GSM711712, GEO:GSM784569, GEO:GSM851913, GEO:GSM886918, GEO:GSM887984, GEO:GSM1001485, GEO:GSM1291130, GEO:GSM1669661, GEO:GSM3161712, GEO:GSM3161713, IARC_TP53:1416, IARC_TP53:28485, IARC_TP53:30197, IGRhCellID:CaOv3, IZSLER:BS TCL 165, KCB:KCB 2013041YJ, LiGeA:CCLE_499, LINCS_LDP:LCL-1519, PharmacDB:Caov3_182_2019, PRIDE:PXD003668, PRIDE:PXD030304, Progenetix:CVCL_0201, PubChem_Cell_line:CVCL_0201, Ubigen:YC-C031, Wikidata:Q54808585

ID: CVCL_0201

Record Creation Time: 20220427T215440+0000

Record Last Update: 20260905T174517+0000

Ratings and Alerts

No rating or validation information has been found for Caov-3.

No alerts have been found for Caov-3.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 250 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. Cell reports. Medicine, 7(4), 102694.

Gjerde CH, et al. (2026) A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. EBioMedicine, 124, 106135.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Zhang F, et al. (2026) The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. *Oncogenesis*, 15(1).

Li Q, et al. (2026) KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment. *Cancer science*.

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. *Cancer discovery*, 16(1), 135.

Aobulikasimu N, et al. (2026) Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. *Materials today. Bio*, 37, 102924.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. *Cell reports*, 45(4), 117198.

Jorgensen A, et al. (2026) Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. *Advanced biology*, 10(3), e00404.

Santer FR, et al. (2026) Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cells. *Scientific reports*, 16(1).

Davies LT, et al. (2025) Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells. *Molecular oncology*, 19(4), 1170.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Littler S, et al. (2025) Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. *iScience*, 28(6), 112555.

Jiang Y, et al. (2025) VIPAS39 confers ferroptosis resistance in epithelial ovarian cancer through exporting ACSL4. *EBioMedicine*, 114, 105646.

Wei W, et al. (2025) Hypoxia-mediated high expression of TRIM15 promotes malignant progression of high-grade serous ovarian cancer through activation of AKT signaling pathway by K63 ubiquitination. *International journal of cancer*, 156(12), 2401.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(18), 3864.

Niemira M, et al. (2025) Adenosine-to-inosine editing of miR-200b-3p is associated with the progression of high-grade serous ovarian cancer. *Molecular oncology*.

Wang M, et al. (2025) Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer. *Open medicine (Warsaw, Poland)*, 20(1), 20251266.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Doro Pereira L, et al. (2025) PARP Inhibitors Differentially Regulate Immune Responses in Distinct Genetic Backgrounds of High-Grade Serous Tubo-Ovarian Carcinoma. *Cancer research communications*, 5(2), 339.